TransCode Therapeutics (NASDAQ:RNAZ) Price Target Raised to $20.00

TransCode Therapeutics (NASDAQ:RNAZ) had its target price hoisted by equities research analysts at HC Wainwright from $3.00 to $20.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 463.38% from the stock’s current price.

TransCode Therapeutics Stock Down 43.8 %

TransCode Therapeutics stock traded down $2.77 during trading hours on Wednesday, reaching $3.55. 576,034 shares of the stock were exchanged, compared to its average volume of 39,469. The firm’s 50 day moving average is $423.06 and its 200 day moving average is $573.64. TransCode Therapeutics has a 52-week low of $3.21 and a 52-week high of $264.00.

Hedge Funds Weigh In On TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management lifted its holdings in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 as of its most recent SEC filing.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.